Menu
Search Close

News

Helium Special Situations increases interest in Scancell

17th November 2011

Holdings in Company

 The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.

 For further information contact:

 Scancell Holdings Plc 

Professor Lindy Durrant/Dr Richard Goodfellow

+ 44 (0)207 245 1100

 

Hansard Communications- Financial PR 

Adam Reynolds/Guy McDougall

+ 44 (0)207 245 1100

 

Zeus Capital - Nominated Adviser

Ross Andrews/Tom Rowley

+ 44 (0)161 831 1512

 

XCAP Securities Plc - Broker

Jon Belliss/ Adrian Kirk

+44 (0) 207 101 7070

Webcasts, Interviews and Media Coverage

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

Wed, 23 May 2018 05:28:00

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

Wed, 18 Apr 2018 12:18:00

Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline

Wed, 18 Apr 2018 13:15:00